EURETINA Innovation Spotlight (EIS)
Wednesday 3 September 2025
Le Palais des Congrès, Paris
EIS 2025
Programme Outline
The EIS Programme will take place in Room Regency AB, on the 4th floor of the Congress Centre.
12:00 – 13:00
Welcome & Registration
13:00 – 13:05
Opening
Anat Loewenstein, President Euretina
Kourous Rezaei, EIS Committee
13:05 – 13:35
SESSION: Non-Neovascular AMD
Moderators: Kourous Rezaei & Frank Holz
13:05
Andrew Want, Astellas Pharma Inc.
Astellas Ophthalmology - Pioneering Novel Approaches in Ophthalmic Therapies
13:10
Reza Safaei, Apellis
Apellis: Committed to Saving Retina and Preserving Function in GA
13:15
Ralf Hornig, Science Corporation
Restoration of vision with the PRIMA Retina Implant System in Patients with Geographic Atrophy
13:20
Panel Discussion / Q&A
13:35 – 14:20
SESSION: VEGF Related Retinal Indications
Moderators: Anat Loewenstein & Francesco Bandello
13:35
Marina Mesquida, Roche
Tackling inflammation in retinal diseases: IL-6 and beyond
13:40
Kevin Douglas, AbbVie
Preserving and Protecting Vision For a Lifetime
13:45
Dhaval Desai, 4D Molecular Therapeutics
4DMT – Powering the Future of Genetic Medicines for the Treatment of Retinal Disease
13:50
Lejla Vajzovic, Adverum
Is Injection Freedom a Realistic Goal for Patients with Wet AMD?
13:55
Sergio Leal, Bayer
Future focus: Bayer's vision in ophthalmology
14:00
Charles Wykoff, Retina Consultants of Texas
A Study of Intravitreal 0.19mg Fluocinolone Acetonide Implant as Baseline Therapy in Patients with Early Diabetic Macular Edema (DME) NEW DAY
14:05
Panel Discussion / Q&A
14:20 – 14:55
SESSION: Inherited and Rare Retinal Diseases
Moderators: Bart Leroy & Caroline Klaver
14:20
Rich Small, Neurotech
Neurotech Company Overview
14:25
Lejla Vajzovic, Ocugen
Ocugen: Novel Modifier Gene Therapy for the Treatment of Retinitis Pigmentosa, Stargardt Disease, and Geographic Atrophy
14:30
Sam Barone, Nanoscope Therapeutics
Multi-Characteristic Opsins - Next Generation Gene Therapy for Vision Restoration
14:35
Peter Francis, Ray Therapeutics
Development of Bioengineered Intravitreal Optogenetic Gene Therapies for Vision Restoration in Retinal Degenerative Diseases
14:40
Panel Discussion / Q&A
14:55 – 15:15
SESSION: Keynote Lecture by Jane Moseley
Moderators: Kourous Rezaei & Ulrich Granzer
14:55
Keynote Lecture: Jane Moseley
EU Regulatory Perspectives on Clinical Endpoints
15:05
Panel Discussion / Q&A
15:15 – 15:30
SESSION: Investor Panel
Moderators: Kourous Rezaei & Martin Zinkernagel
Round Table Discussion: Elisa Petris / Syncona, Michaël Vlemmix / Life Sciences Gimv, Roger Zhang / Samsara Biocapital
15:30 – 16:00
BREAK
16:00 – 16:55
SESSION: VEGF Related and Other Retinal Indications
Moderators: Nicole Eter & Patricia Udaondo
16:00
Peter K. Kaiser, Ocular Therapeutix
Ocular Therapeutix: Redefining the Retina Experience
16:05
Scott Jones, EyePoint Pharmaceuticals
EyePoint is Committed to Developing Therapeutics to Help Improve the Lives of Patients with Serious Retinal Disease
16:10
Bob Jahr, Outlook Therapeutics
Outlook Therapeutics: Optimising the treatment of retinal disease
16:15
Sherri Van Everen, REGENXBIO
Gene therapy for unmet needs in retinal disease
16:20
Sharon Klier, Oculis
Oculis’ Commitment to Ophthalmology – Building an Innovative Pipeline
16:25
Anders Haegerstrand, Annexin Pharmaceuticals
Novel therapy for retinal vascular diseases, Annexin A5
16:30
Brad Doerschuk, InFocus Clinical Research
Retina Revolution: Ensuring Clinical Trial Success in a Competitive Arena
16:35
Patrick Bussfeld, Boehringer Ingelheim
Advancing Ophthalmology beyond Anti-VEGF
16:40
Panel Discussion
16:55 – 17:40
SESSION: Innovations in Retinal Surgery and Imaging
Moderators: Alistair Laidlaw & Grazia Pertile
16:55
Dimitris Aktypis, Alcon
Superior efficiency for vitreoretinal and cataract surgery
17:00
Pierre Billardon, DORC
The Future of Retina Surgery: Advancing Workflow-Driven Innovation
17:05
Anne Marie Cairns, Optos
Beyond the Horizon: Pioneering Innovation in Retina for Tomorrow’s World
17:10
Georgy Shakirin, ZEISS Medical Technology
How Connected Data and AI Are Essential to Ophthalmic Innovation and Care
17:15
Stephanie Magazzeni, Heidelberg Engineering
Multimodality & High Resolution: The Ground Truth for Reliable Imaging & AI
17:20
Petri Huhtinen, Optomed
Optomed’s AI Enabled Camera Innovations – A Key to Advancing Oculomics & Early Detection
17:25
Panel Discussion / Q&A
17:40 – 18:04
SESSION: Rapid Fire Panel Discussion
Moderators: Martin Zinkernagel & Arshad Khanani
17:40
Natalia Misciattelli, AAVantgarde
AAVantgarde: Pioneering large-gene delivery through proprietary & innovative AAV-based platforms, to improve the lives of patients with debilitating diseases
17:42
Muhammad Ali Memon, Complement Therapeutics
CTx001, a novel complement modulator gene therapy for Geographic Atrophy (GA)
17:44
Michael O’Rourke, Re-Vana Therapeutics
Re-Vana Therapeutics: Advancing Sustained Release Biologics for Treatment of Serious Retinal Disease
17:46
Wesley Jackson, Valitor
Engineering a new generation of durable ophthalmic medicines based on multivalent conjugation to hyaluronic acid
17:48
Morgane Rousselot, SeaBeLife Biotech
A first-in-class small molecule as topical non invasive therapy for Geographic Atrophy targeting regulated necrotic cell death
17:50
Luis Lesmes, Adaptive Sensory Technology
AST Manifold: An Active Machine Learning Platform for Visual Function Endpoints
17:52
Kali Stasi, SparingVision
SparingVision’s Gene-Agnostic Gene Therapy Approach
17:54
Panel Discussion / Q&A
18:04
Closing Remarks
Nicole Eter
18:05
Networking & Poster Exhibition
Poster exhibition by:
Coave Therapeutics
Galimedix Therapeutics Inc.
Gerresheimer AG,
Ikarovec
MgShell S.r.l
Please note, this programme may be subject to change.